ALNY

Alnylam Pharmaceuticals' stock price experienced fluctuations between November 2025 and May 2026. The stock closed at $451.23 in November 2025 and reached a high of $397.65 in December 2025, before closing at $295.05 in May 2026. In February 2026, Alnylam reported strong fourth quarter and full-year 2025 financial results, achieving global net product revenues of nearly $3 billion, an 81% increase year-over-year, and reaching profitability, driven by increased demand for AMVUTTRA. In April 2026, the company announced its Q1 2026 earnings, reporting $1.99 EPS and revenue of $1.17 billion, up approximately 96% year-over-year; however, the stock price dipped due to investors focusing on reiterated full-year 2026 net product revenue guidance. The 52-week high for ALNY stock was $495.55, and the 52-week low was $252.79.